Analytical Validation of an Automated Semiconductor-Based Next-Generation Sequencing Assay for Detection of DNA and RNA Alterations in Myeloid Neoplasms

Khoury, 2022, The 5th edition of the World Health Organization classification of haematolymphoid tumours: myeloid and histiocytic/dendritic neoplasms, Leukemia, 36, 1703, 10.1038/s41375-022-01613-1 Döhner, 2022, Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN, Blood, 140, 1345, 10.1182/blood.2022016867 Bejar, 2011, Clinical effect of point mutations in myelodysplastic syndromes, N Engl J Med, 364, 2496, 10.1056/NEJMoa1013343 Papaemmanuil, 2013, Clinical and biological implications of driver mutations in myelodysplastic syndromes, Blood, 122, 3616, 10.1182/blood-2013-08-518886 Reinig, 2016, Targeted next-generation sequencing in myelodysplastic syndrome and chronic myelomonocytic leukemia aids diagnosis in challenging cases and identifies frequent spliceosome mutations in transformed acute myeloid leukemia, Am J Clin Pathol, 145, 497, 10.1093/ajcp/aqw016 Arber, 2022, International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data, Blood, 140, 1200, 10.1182/blood.2022015850 Daver, 2019, Targeting FLT3 mutations in AML: review of current knowledge and evidence, Leukemia, 33, 299, 10.1038/s41375-018-0357-9 Papaemmanuil, 2016, Genomic classification and prognosis in acute myeloid leukemia, N Engl J Med, 374, 2209, 10.1056/NEJMoa1516192 Döhner, 2017, Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel, Blood, 129, 424, 10.1182/blood-2016-08-733196 Klampfl, 2013, Somatic mutations of calreticulin in myeloproliferative neoplasms, N Engl J Med, 369, 2379, 10.1056/NEJMoa1311347 Kralovics, 2005, A gain-of-function mutation of JAK2 in myeloproliferative disorders, N Engl J Med, 352, 1779, 10.1056/NEJMoa051113 Nangalia, 2013, Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2, N Engl J Med, 369, 2391, 10.1056/NEJMoa1312542 Au, 2016, Clinical evaluation of panel testing by next-generation sequencing (NGS) for gene mutations in myeloid neoplasms, Diagn Pathol, 11, 11, 10.1186/s13000-016-0456-8 Bartels, 2016, Routine clinical mutation profiling using next generation sequencing and a customized gene panel improves diagnostic precision in myeloid neoplasms, Oncotarget, 7, 30084, 10.18632/oncotarget.8310 Kluk, 2016, Validation and implementation of a custom next-generation sequencing clinical assay for hematologic malignancies, J Mol Diagn, 18, 507, 10.1016/j.jmoldx.2016.02.003 Thomas, 2017, Integration of technical, bioinformatic, and variant assessment approaches in the validation of a targeted next-generation sequencing panel for myeloid malignancies, Arch Pathol Lab Med, 141, 759, 10.5858/arpa.2016-0547-RA McClure, 2018, Clinical significance of DNA variants in chronic myeloid neoplasms: a report of the Association for Molecular Pathology, J Mol Diagn, 20, 717, 10.1016/j.jmoldx.2018.07.002 Tallman, 2019, Acute myeloid leukemia, version 3.2019, NCCN Clinical Practice Guidelines in Oncology, J Natl Compr Canc Netw, 17, 721, 10.6004/jnccn.2019.0028 Izevbaye, 2020, Clinical validation of a myeloid next-generation sequencing panel for single-nucleotide variants, insertions/deletions, and fusion genes, J Mol Diagn, 22, 208, 10.1016/j.jmoldx.2019.10.002 Bhai, 2022, Clinical utility of implementing a frontline NGS-based DNA and RNA fusion panel test for patients with suspected myeloid malignancies, Mol Diagn Ther, 26, 333, 10.1007/s40291-022-00581-7 Sande, 2023, Rapid and automated semiconductor-based next-generation sequencing for simultaneous detection of somatic DNA and RNA aberrations in myeloid neoplasms, J Mol Diagn, 25, 87, 10.1016/j.jmoldx.2022.11.005 Chendamarai, 2012, Role of minimal residual disease monitoring in acute promyelocytic leukemia treated with arsenic trioxide in frontline therapy, Blood, 119, 3413, 10.1182/blood-2011-11-393264